

Supporting information for:

**Synthesis and Characterization of Bis(amidate) Rare-Earth Metal
Amides and the Application in Catalytic Addition of Amines to
Carbodiimides**

Hao Cheng,[†] Yang Xiao,[†] Chengrong Lu,[†] Bei Zhao,^{*,†} Yaorong Wang,[†] Yingming Yao^{*,†}

[†]Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry,
Chemical Engineering and Materials Science, Dushu Lake Campus, Soochow
University, Suzhou 215123, China

Table of contents

	Page
1. General methods	S-1
2. Procedures for the preparation of complexes 4-5	S-1
3. X-ray structure determination of complexes	S-1
4. Figures Structures of bridged bisamidate rare-earth metal amides	S-2
5. Table 1 Crystallographic data for complexes	S-3
6. Table 2 Selected bond lengths and bond angles	S-4
7. The characterization data of the guanidine products	S-4
8. Reference	S-8

General Methods

All manipulations and reactions were conducted under purified argon atmosphere by using vacuum line techniques or in a glovebox. Rare-earth metal precursors $\text{RE}[\text{N}(\text{SiMe}_3)_2]_3$ (RE = La, Nd, Sm, Yb, Y), and proligand N,N'-(cyclohexane-1,2-diyl)bis(4-*tert*-butylbenzamide) were prepared according to literature methods^[1]. Solvents were distilled from sodium benzophenone ketyl under argon prior to use. Solid amines were degassed before use, and liquid amines were distilled from CaH_2 prior to use. The single crystal X-ray diffraction data were recorded on a Rigaku Mercury CCD X-ray diffractometer. ^1H and ^{13}C NMR spectra were obtained on a Bruker-400 spectrometer in CDCl_3 . Metal analyses were carried out by complexometric titration. Carbon, hydrogen, and nitrogen analyses were performed by direct combustion on a Carlo-Erba EA-1110 instrument. Melting points for the complexes were determined in sealed Ar-filled capillary tubes and are uncorrected.

*Synthesis of $\{\text{LSm}[\text{N}(\text{SiMe}_3)_2] \cdot \text{THF}\}_2$ (**4**)*

To a stirred tetrahydrofuran solution of $\text{Sm}[\text{N}(\text{SiMe}_3)_2]_3$ (1.50 mmol, 10 mL of THF), N,N'-(cyclohexane-1,2-diyl)bis(4-*tert*-butylbenzamide) (0.66 g, 1.50 mmol) in 10 mL THF was slowly added. After the mixture was stirred at 25 °C for 24 h, the solvent was pumped off, and the residue was recrystallized from THF at room temperature to give **4** as colourless crystals.

*Synthesis of $\{\text{LYb}[\text{N}(\text{SiMe}_3)_2] \cdot \text{THF}\}_2$ (**5**)*

Following the method described for complex **4**, reaction of N,N'-(cyclohexane-1,2-diyl)bis(4-*tert*-butylbenzamide) (0.62 g, 1.40 mmol) and $\text{Yb}[\text{N}(\text{SiMe}_3)_2]_3$ (1.40 mmol, 10 mL of THF), afforded colourless crystals **5** in THF.

*X-ray structure determination of complexes **4-5***

Owing to their air and moisture sensitivity, suitable single crystals of complexes **4-5** were each sealed in thin-walled glass capillaries. Intensity data were collected on a Rigaku Mercury CCD equipped with graphite-monochromatized Mo $\text{K}\alpha$ ($\lambda =$

0.71075 Å) radiation. Details of the intensity data collection and crystal data are given in Tables 1 and 2. The crystal structures of these complexes were solved by direct methods and expanded by Fourier techniques. Atomic coordinates and thermal parameters were refined by fullmatrix least-squares analysis on F^2 . All the non-hydrogen atoms were refined anisotropically. Hydrogen atoms were all generated geometrically with assigned appropriate isotropic thermal parameters. The structures were solved and refined by using the SHELXL-97 program [2].




Figure 1. Structure of bridged bisamidate samarium amide **4·3THF**. Hydrogen atoms and the molecule of THF in the unit cell are omitted for clarity.




Figure 2. Structure of bridged bisamidate ytterbium amide **5·3THF**. Hydrogen atoms and the molecule of THF in the unit cell are omitted for clarity.

Table 1. Crystallographic data and structure refinement details for complexes **4-5**.

	4•3C₄H₈O	5•3C₄H₈O
Empirical formula	C ₈₈ H ₁₄₈ N ₆ O ₉ Si ₄ Sm ₂	C ₈₈ H ₁₄₈ N ₆ O ₉ Si ₄ Yb ₂
Fw	1847.18	1892.56
Temperature (K)	293(2)	293(2)
Wavelength (Å)	0.71073	0.71075
Crystal system	Triclinic	Triclinic
Space group	P -1	P -1
Crystal size (mm)	0.75 × 0.4 × 0.2	0.8 × 0.4 × 0.2
	13.7002(6)	13.700(16)
a, b, c (Å)	13.9301(8)	14.00(3)
	15.2548(5)	15.31(2)
	108.997(4)	109.37(4)
α, β, γ (deg)	106.363(4)	105.895(8)
	97.835(4)	98.64(2)
Volume (Å ³)	2556.4(2)	2569(7)
Z	1	1
Calculated density (g/cm ³)	1.200	1.224
Absorption coefficient (mm ⁻¹)	1.234	1.906
<i>F</i> (000)	970	986
θ range (deg)	5.756-51	6.016-54.974
	-16 ≤ h ≤ 16,	-17 ≤ h ≤ 17,
Limiting indices	-16 ≤ k ≤ 15,	-18 ≤ k ≤ 14,
	-18 ≤ l ≤ 18	-19 ≤ l ≤ 19
Reflections collected	24937	23938
	9499	11585
Unique	[R(int) = 0.0313]	[R(int) = 0.0379]
Max. and Min. transmission	1.000 and 0.704	0.473 and 0.319
Data/restraints/ parameters	9499/243/601	11585/341/619

GOF on F ²	1.128	1.085
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0349$, $wR_2 = 0.0979$	$R_1 = 0.0492$, $wR_2 = 0.1178$
R indices (all data)	$R_1 = 0.0432$, $wR_2 = 0.1012$	$R_1 = 0.0601$, $wR_2 = 0.1272$
Largest diff. Peak and hole (e/Å ³)	1.00 and -0.43	0.92 and -1.3

Table 2 Selected bond lengths (Å) and bond angles (°) for complexes **4-5**.

	4•3C₄H₈O	5•3C₄H₈O
Ln(1)-O(1)	2.196(3)	2.113(4)
Ln(1)-N(3)	2.309(3)	2.219(5)
Ln(1)-O(2A)	2.363(3)	2.265(4)
Ln(1)-O(3)	2.494(3)	2.393(5)
Ln(1)-N(2)	2.501(3)	2.405(5)
Ln(1)-O(2)	2.551(3)	2.467(5)
O(1)-C(1)	1.327(4)	1.320(6)
O(2)-C(18)	1.332(4)	1.323(6)
N(1)-C(1)	1.274(5)	1.283(7)
N(2)-C(18)	1.282(5)	1.302(6)
O(1)- Ln(1)-O(3)	79.47(10)	78.52(18)
O(3)- Ln(1)-O(2A)	76.68(10)	77.00(18)
O(2A)- Ln(1)-N(2)	117.03(10)	117.85(17)
N(2)- Ln(1)-O(1)	77.51(10)	79.13(19)
N(3)- Ln(1)-O(2)	134.63(11)	135.98(16)
O(2A)- Ln(1)-O(2)	66.13(9)	65.68(15)

The characterization data of the guanidine products

1,3-diisopropyl-2-phenylguanidine (**7a**). ¹H NMR (400 MHz, CDCl₃): δ 7.29-7.20 (m, 2H); 6.93 (t, $J = 7.4$ Hz, 1H); 6.86 (d, $J = 7.4$ Hz, 2H); 3.77 (s, 2H); 3.59 (s, 2H); 1.16 (d, $J = 6.3$ Hz, 12H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 150.5, 150.4, 129.3, 123.6, 121.4, 43.3, 23.4 ppm.

1,3-dicyclohexyl-2-phenylguanidine (**7b**). ^1H NMR (400 MHz, CDCl_3): δ 7.25-7.21 (m, 2H); 6.95-6.95-6.89 (m, 1H); 6.88-6.86 (m, 2H); 3.65 (s, 2H); 3.42 (s, 2H); 2.01-1.12 (m, 20H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.7, 150.7, 129.5, 123.9, 121.6, 50.5, 34.1, 26.0, 25.2 ppm.

1,3-diisopropyl-2-p-tolylguanidine (**7c**). ^1H NMR (400 MHz, CDCl_3): δ 7.05 (d, J = 7.6 Hz, 2 H); 6.74 (d, J = 7.6 Hz, 2 H); 3.76 (s, 2H); 3.56 (s, 2H); 2.28 (s, 3H); 1.16 (d, J = 7.6 Hz, 12 H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 153.2, 147.6, 130.5, 129.9, 123.3, 43.2, 23.4, 20.8 ppm.

1,3-diisopropyl-2-o-tolylguanidine (**7d**). ^1H NMR (400 MHz, CDCl_3): δ 7.14 (d, J = 7.4 Hz, 1H); 7.09 (t, J = 7.5 Hz, 1H); 6.87 (t, J = 7.0 Hz, 1H); 6.76 (d, J = 7.7 Hz, 1H); 3.76 (s, 2H); 3.44 (s, 1H); 2.14 (s, 3H); 1.16 (d, J = 6.4 Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 148.9, 148.4, 130.5, 130.4, 126.6, 123.2, 121.8, 43.2, 23.5, 18.1 ppm.

1,3-dicyclohexyl-2-o-tolylguanidine (**7e**). ^1H NMR (400 MHz, CDCl_3): δ 6.93 (m, 2H); 6.78 (m, 2H); 3.62 (br, 2H); 3.40 (br, 2H); 2.00 (s, 3H); 1.97-1.03 (m, 20H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 148.94, 148.70, 131.86, 130.60, 126.84, 123.48, 121.88, 50.40, 34.18, 25.94, 25.22, 18.41 ppm.

1,3-diisopropyl-2-(4-methoxyphenyl)guanidine (**7f**). ^1H NMR (400 MHz, CDCl_3): δ 6.83-6.76 (m, 4H); 3.77 (s, 5H); 3.57 (s, 2H); 1.16-1.14 (m, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 154.7, 150.9, 143.4, 124.5, 114.8, 55.6, 43.4, 23.6 ppm.

2-(2-chlorophenyl)-1,3-diisopropylguanidine (**7g**). ^1H NMR (400 MHz, CDCl_3): δ 7.34 (d, J = 7.7 Hz, 1H); 7.14 (t, J = 7.3 Hz, 1H); 7.0-6.7 (m, 2H); 3.79 (dd, J = 12.3, 6.1 Hz, 2H); 3.47 (s, 2H); 1.16 (d, J = 6.3 Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 149.9, 147.0, 130.0, 128.4, 127.5, 125.3, 122.5, 43.3, 23.5 ppm.

2-(2-chlorophenyl)-1,3-dicyclohexylguanidine (**7h**). ^1H NMR (400 MHz, CDCl_3): δ 7.34-7.33 (m, 1H), 7.15-7.11 (m, 1H); 6.92-6.85 (m, 2H); 3.56 (s, 2H); 3.42 (s, 2H); 2.05-1.06 (m, 20H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.1, 147.6, 130.1, 128.7, 127.8, 125.6, 122.6, 50.5, 34.1, 26.0, 25.2 ppm.

2-(4-chlorophenyl)-1,3-diisopropylguanidine (**7i**). ^1H NMR (400 MHz, CDCl_3): δ 7.19 (d, $J = 8.5$ Hz, 2H); 6.77 (d, $J = 8.5$ Hz, 2H); 3.80-3.68 (m, 2H); 3.54 (s, 2H); 1.16 (d, $J = 6.3$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.5, 148.9, 129.4, 126.3, 124.7, 43.2, 23.4 ppm.

2-(4-bromophenyl)-1,3-diisopropylguanidine (**7j**). ^1H NMR (400 MHz, CDCl_3): δ 7.33 (d, $J = 8.4$ Hz, 2 H); 6.73 (d, $J = 8.4$ Hz, 2 H); 3.82-3.67 (m, 2 H); 3.54 (s, 2H); 1.16 (d, $J = 6.3$ Hz, 12 H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.2, 149.6, 132.2, 125.4, 113.9, 43.2, 23.4 ppm.

2-(4-fluorophenyl)-1,3-diisopropylguanidine (**7k**). ^1H NMR (400 MHz, CDCl_3): δ 6.94 (t, $J = 8.7$ Hz, 2H); 6.82-6.73 (m, 2H); 3.75 (s, 2H); 3.52 (s, 2H); 1.16 (d, $J = 6.3$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.5, 146.0, 141.8, 124.5, 124.4, 115.8, 115.6, 43.2, 23.4 ppm.

1,3-dicyclohexyl-2-(4-fluorophenyl)guanidine (**7l**). ^1H NMR (400 MHz, CDCl_3): δ 6.94-6.90 (m, 2 H); 6.77-6.73 (m, 2 H); 3.59 (s, 2 H); 3.38-3.36 (m, 2 H); 1.99-1.03 (m, 20 H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.6, 124.9, 124.8, 116.1, 115.9, 50.4, 34.1, 25.9, 25.2 ppm.

1,3-diisopropyl-2-(naphthalen-1-yl)guanidine (**7m**). ^1H NMR (400 MHz, CDCl_3): δ 8.07 (d, $J = 8.0$ Hz, 1H); 7.79 (d, $J = 7.6$ Hz, 1H); 7.35-7.47 (m, 4H); 6.92 (d, $J = 7.2$ Hz, 1H); 3.88 (brs, 2H); 3.63 (brs, 2H); 1.18 (d, $J = 6.4$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.2, 147.1, 135.1, 129.9, 128.1, 126.8, 126.1, 124.9, 124.7, 121.7, 118.1, 43.6, 23.7 ppm.

1,3-diisopropyl-2-(4-nitrophenyl)guanidine (**7n**). ^1H NMR (400 MHz, CDCl_3): δ 8.10 (d, $J = 8.9$ Hz, 2H); 6.89 (d, $J = 8.9$ Hz, 2H); 3.79 (s, 4H); 1.20 (s, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 158.3, 150.4, 140.9, 125.6, 122.8, 43.3, 23.2 ppm.

1,3-diisopropyl-2-(3-nitrophenyl)guanidine (**7o**). ^1H NMR (400 MHz, CDCl_3): δ 7.83-7.66 (m, 1H); 7.36 (t, $J = 8.0$ Hz, 1H); 7.17 (d, $J = 7.7$ Hz, 1H); 3.78 (dd, $J = 12.9$, 6.4 Hz, 2H); 3.60 (d, $J = 6.0$ Hz, 2H); 1.19 (s, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 152.0, 150.4, 149.3, 130.1, 129.7, 118.1, 115.8, 43.4, 23.4 ppm.

1,3-diisopropyl-2-(4-methyl-2-nitrophenyl)guanidine (**7p**). ^1H NMR (400 MHz, CDCl_3): δ 7.62 (s, 1H); 7.21 (d, $J = 9.6$ Hz, 1H); 6.86 (d, $J = 8.1$ Hz, 1H); 3.75 (dd, $J = 13.4$, 6.7 Hz, 2H); 3.52 (d, $J = 7.1$ Hz, 2H); 2.32 (s, 3H); 1.17 (d, $J = 6.4$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 150.3, 143.5, 142.7, 134.4, 130.8, 126.8, 125.2, 43.4, 23.4, 20.4 ppm.

2-(3,5-bis(trifluoromethyl)phenyl)-1,3-diisopropylguanidine (**7q**). ^1H NMR (400 MHz, CDCl_3): δ 7.37 (s, 1H), 7.28 (s, 2H), 3.78 (dq, $J = 12.8$, 6.5 Hz, 2H), 3.61 (d, $J = 7.4$ Hz, 2H), 1.19 (d, $J = 6.4$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 152.2, 150.6, 132.7, 132.4, 132.1, 131.7, 127.6, 124.9, 123.4, 122.2, 119.5, 113.9, 43.3, 23.2 ppm.

1,3-diisopropyl-2-(perfluorophenyl)guanidine (**7r**). ^1H NMR (400 MHz, CDCl_3): δ 3.80 (dq, $J = 12.8$, 6.4 Hz, 2H), 3.61 (d, $J = 7.2$ Hz, 2H), 1.20 (d, $J = 6.4$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 151.2, 141.9, 139.6, 138.9, 136.4, 133.8, 126.2, 124.9, 124.5, 43.1, 22.6 ppm.

2-(2,6-diisopropylphenyl)-1,3-diisopropylguanidine (**7s**). ^1H NMR (400 MHz, CDCl_3): δ 7.07-7.03 (m, 2H); 6.96-6.90 (m, 1H); 4.13 (s, 2H); 3.44-3.10 (m, 2H); 3.10-3.05 (m, 2H); 1.25-1.04 (m, 24H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 147.7, 144.3, 141.6, 123.2, 122.3, 43.5, 42.7, 28.0, 23.9 ppm.

1,3-diisopropyl-2-(pyridin-2-yl)guanidine (**7t**). ^1H NMR (400 MHz, CDCl_3): δ 8.07 (dd, $J = 5.1, 1.4$ Hz, 1H); 7.42 (ddd, $J = 8.4, 7.1, 2.1$ Hz, 1H); 6.83 (d, $J = 8.3$ Hz, 1H); 6.61 (ddd, $J = 7.0, 5.1, 1.0$ Hz, 1H); 3.93 (d, $J = 4.5$ Hz, 2H); 1.25 (d, $J = 6.4$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 163.6, 153.8, 136.7, 120.3, 114.0, 42.6, 23.5 ppm.

(Z)-N,N'-diisopropylindoline-1-carboximidamide (**7u**). ^1H NMR (400 MHz, CDCl_3): δ 7.18 (d, $J = 7.5$ Hz, 1H); 7.13-7.02 (m, 2H); 6.75 (t, $J = 7.2$ Hz, 1H); 3.95-3.70 (m, 2H); 3.55-3.30 (m, 2H); 3.15-2.90 (m, 2H); 1.14 (d, $J = 5.9$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 149.3, 146.0, 130.9, 126.5, 124.0, 119.0, 111.0, 50.0, 46.6, 45.1, 27.3, 24.3, 23.3 ppm.

(Z)-N,N'-diisopropylpyrrolidine-1-carboximidamide (**7v**). ^1H NMR (400 MHz, CDCl_3): δ 3.39-3.28 (m, 2H); 3.26-3.16 (m, 4H); 1.80-1.71 (m, 4H); 1.06 (d, $J = 6.4$ Hz, 12H) ppm. ^{13}C NMR (100 MHz, CDCl_3): δ 153.6, 47.9, 46.6, 25.1, 24.6 ppm.

Reference:

- [1] S. P. Anthony, K. Basavaiah, T. P. Radhakrishnan. *Crystal Growth & Design*, **2005**, 5, 1663–1665.
- [2] G.M. Sheldrick, SHELXL-2013, Program for the Refinement of Crystal Structures, University of Göttingen, Germany, 2013.